Mustang Bio, Inc. - MBIO STOCK NEWS

Mustang Bio, Inc. (NASDAQ: MBIO) announced promising interim data from a Phase 1/2 clinical trial of MB-106, a CD20-targeted CAR T cell therapy for relapsed or refractory B-NHLs and CLL. The therapy demonstrated a 94% overall response rate and a 78% complete response rate in patients with follicular lymphoma. Additionally, it achieved a 100% overall response rate in other B-cell malignancies. The trial showcases a favorable safety profile, making MB-106 a viable outpatient treatment option. Enrollment for the study remains open.

Mustang Bio (NASDAQ: MBIO) has announced encouraging interim results from a Phase 1/2 clinical trial for its gene therapy MB-107, aimed at treating X-linked severe combined immunodeficiency (XSCID). The trial included 23 infants, all of whom are alive and have shown complete hematopoietic recovery without signs of malignant transformation at a median follow-up of 2.6 years. The company plans to initiate a pivotal Phase 2 trial later this year, further validating the therapy's safety and efficacy.

Mustang Bio, Inc. (NASDAQ: MBIO) reported financial results for Q1 2022, revealing a net loss of $19.8 million ($0.20 per share), up from $15.0 million ($0.19 per share) a year earlier. As of March 31, 2022, cash reserves rose to $123.2 million, an increase of $12.6 million year-to-date. Significant clinical data were presented at major conferences, showing a 96% overall response rate for MB-106 in B-cell NHL and CLL. Upcoming presentations are scheduled for EHA2022 and ASGCT. Mustang aims to start several clinical trials for MB-106 and MB-107 later this year, reflecting strong progress in its development pipeline.

Mustang Bio (MBIO) announced results from the Phase 1/2 trial of MB-106, a CD20-targeted CAR T cell therapy for relapsed or refractory follicular lymphoma (FL), to be presented at EHA2022. Dr. Mazyar Shadman will provide updated patient data, indicating a favorable safety profile and notable response rates. The trial is progressing with expanding enrollment criteria, which includes CAR T naïve patients and those previously treated. Mustang anticipates dosing the first patient in a multicenter trial evaluating MB-106's safety and efficacy this quarter.

Mustang Bio announced significant interim Phase 1/2 clinical trial results for its lentiviral gene therapy, MB-107, targeting X-linked severe combined immunodeficiency (XSCID). The data highlights a cohort of 23 infants, all still alive, with 20 showing recovery from pre-existing infections and normal growth. Seventeen of 18 patients with over six months of follow-up achieved robust immune reconstitution. The presentation will be held at the ASGCT Annual Meeting on May 19, 2022, with plans to initiate a pivotal Phase 2 trial later in 2022.

Mustang Bio, Inc. (NASDAQ: MBIO) announced promising interim data from a Phase 1/2 clinical trial of MB-106, a CD20-targeted CAR T cell therapy for relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. The study demonstrated a 96% overall response rate and a 72% complete response rate, with a favorable safety profile across all 25 patients. Notably, previous CAR T therapy patients also responded well. The company plans to dose the first patient in a multicenter trial this quarter, indicating potential for outpatient treatment.

Mustang Bio (NASDAQ: MBIO) announced that Dr. Mazyar Shadman will present interim data on MB-106, a CD20-targeted CAR T-cell therapy for relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia, at two key conferences. The presentations will occur at the 2022 Tandem Meetings (April 23-26) and iwCAR-T (April 28-May 1). Initial findings indicate promising clinical efficacy and safety of MB-106, which is in a Phase 1/2 trial at Fred Hutch. The company plans to start a multicenter trial under its IND soon. The autologous CAR-T therapy was collaboratively developed with Fred Hutch.

Mustang Bio (NASDAQ: MBIO) announced positive interim results from ongoing Phase 1 clinical trials of MB-101 (a CAR T cell therapy) and MB-108 (an oncolytic virus) for recurrent glioblastoma (rGBM). Research presented by Dr. Christine Brown at the AACR Annual Meeting 2022 indicates these therapies are well tolerated, with preliminary safety data supporting the development of a combination therapy, MB-109, which aims to enhance treatment efficacy. Mustang plans to file an Investigational New Drug application for MB-109 later this year, aiming to address the challenges of rGBM treatment.

Mustang Bio, Inc. (NASDAQ: MBIO), a clinical-stage biopharmaceutical firm, announced its participation in the Fortress Biotech Virtual R&D Summit on April 5-6, 2022. Mustang’s management will present a corporate overview and join a panel discussion on April 6 at 1:30 p.m. ET. Interested parties can register for the event here. A webcast will be available for 30 days post-event on the Investor Relations section of Mustang’s website.